Medical Journals

17 Beta-estradiol Modifies Nitric Oxide-sensitive Guanylyl Cyclase Expression and Down-regulates Its Activity in Rat Anterior Pituitary Gland.

Authors:
  • Cabilla Jimena P
  • Díaz María del Carmen
  • Machiavelli Leticia I
  • Poliandri Ariel H
  • Quinteros Fernanda A
  • Lasaga Mercedes
  • Duvilanski Beatriz H

From: Departamento de Química Biológica, Instituto de Química y Fisico Química Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires (C1113AAD), Argentina.

Endocrinology

  • Publish Date: Sep 2006
  • ISSN: 0013-7227
  • Volume: 147
  • Issue: 9
  • Pages: 4311-8
  • Medium: Print
  • Language: English
  • Citation (JAMA): Cabilla Jimena P, Díaz María del Carmen, Machiavelli Leticia I, et al. 17 Beta-estradiol Modifies Nitric Oxide-sensitive Guanylyl Cyclase Expression and Down-regulates Its Activity in Rat Anterior Pituitary Gland.. Endocrinology Sep 2006;147:4311-8

Abstract

Previous studies showed that 17 beta-estradiol (17 beta-E2) regulates the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP pathway in many tissues. Evidence from our laboratory indicates that 17 beta-E2 disrupts the inhibitory effect of NO on prolactin release, decreasing sGC activity and affecting the cGMP pathway in anterior pituitary gland of adult ovariectomized and estrogenized rats. To ascertain the mechanisms by which 17 beta-E2 affects sGC activity, we investigated the in vivo and in vitro effects of 17 beta-E2 on sGC protein and mRNA expression in anterior pituitary gland from immature female rats. In the present work, we showed that 17 beta-E2 acute treatment exerted opposite effects on the two sGC subunits, increasing alpha1 and decreasing beta1 subunit protein and mRNA expression. This action on sGC protein expression was maximal 6-9 h after 17 beta-E2 administration. 17beta-E2 also caused the same effect on mRNA expression at earlier times. Concomitantly, 17 beta-E2 dramatically decreased sGC activity 6 and 9 h after injection. These effects were specific of 17 beta-E2, because they were not observed with the administration of other steroids such as progesterone and 17 alpha-estradiol. This inhibitory action of 17beta-E2 on sGC also required the activation of estrogen receptor (ER), because treatment with the pure ER antagonist ICI 182,780 completely blocked 17 beta-E2 action. 17 beta-E2 acute treatment caused the same effects on pituitary cells in culture. These results suggest that 17 beta-E2 exerts an acute inhibitory effect on sGC in anterior pituitary gland by down-regulating sGC beta 1 subunit and sGC activity in a specific, ER-dependent manner.

Mesh Headings (Keywords): Animals, Cyclic GMP, Down-Regulation, Estradiol, Female, Gene Expression, Guanylate Cyclase, Isoenzymes, Nitric Oxide, Pituitary Gland, Anterior, RNA, Messenger, Rats, Rats, Wistar, Receptors, Estrogen, Solubility


Check for Full Text / PubMed Unique Identifier (PMID): 16740976


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.